Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00289523 · ClinicalTrials.gov registry record
EEG Biomarkers for Predicting Response to Antidepressant Therapy
A clinical trial, sponsored by Medtronic - MITG.
- Completed
- Registry status
- 375
- Enrollment target
NCT00289523: Completed study, sponsored by Medtronic - MITG.
NCT00289523 is a clinical trial that has completed, run by Medtronic - MITG. The registered enrollment target is 375 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00289523 has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- 375 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential early EEG predictors of an individual's response to treatment with antidepressant medications. Objectives: * Prospectively confirm accuracy of current EEG biomarker algorithm * Determine preferred clinical intervention for subjects with negative indicator * Identify predictors of worsening suicide ideation
Primary Outcome
2\. To identify the optimal positive and negative indicators of response to initial treatment with an SSRI; 3. To determine the preferred clinical intervention to perform following an initial negative treatment response indicator;
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-07 |
What the finished NCT00289523 record still lists
NCT00289523 is an observational study that tracks outcomes without assigning an intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00289523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00289523 about?
NCT00289523 is a clinical study titled "EEG Biomarkers for Predicting Response to Antidepressant Therapy". The purpose of this study is to evaluate the potential early EEG predictors of an individual's response to treatment with antidepressant medications. Objectives: * Prospectively confirm accuracy of current EEG biomarker algorithm * Determine preferred clinical intervention for subjects with negati...
What is the current status of trial NCT00289523?
This trial is currently completed. The enrollment target is 375 participants. The study started on 2006-01. Estimated completion is 2007-07.
Who is sponsoring clinical trial NCT00289523?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia